Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 2 NIH 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 Dermatologic 1

Conditions

Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 131 Carboplatin 106 Paclitaxel 66 Cisplatin 61 Gemcitabine 57 Pemetrexed 56 Bevacizumab 50 Docetaxel 47 Fluorouracil 40 Oxaliplatin 38 Dexamethasone 34 130-nm albumin-bound paclitaxel 34 Leucovorin 33 atezolizumab 32 Cetuximab 32 durvalumab 30 Nivolumab 28 Rituximab 26 Cyclophosphamide 26 Capecitabine 26 Prednisone 25 Fulvestrant 24 enzalutamide 23 Lenalidomide 22 venetoclax 21 Letrozole 20 Irinotecan 20 Doxorubicin 17 ribociclib 16 pomalidomide 16

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Vorinostat × 30 days × Clear all

NCT02943642 2026-05-18

Resimmune®

Virogen Biotechnology Inc.

Phase 2 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon ⚡